Advertisement
Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

rEVO Biologics Company Profile

13:13 EDT 19th April 2014 | BioPortfolio

rEVO Biologics is a rare disease company focused on developing and delivering first and next-generation therapeutics that are more cost effective to produce than traditional recombinant therapies. Through its proprietary rPRO Technology platform -- a scalable, transgenic, and cost-effective method of protein production-- rEVO Biologics is bringing safe and reliable therapeutic proteins to address critical medical needs. The company’s lead product, ATryn® Antithrombin (Recombinant), is the first and only plasma-free antithrombin concentrate. ATryn received FDA approval in 2009. The company has a number of products in its pipeline and in clinical trials in the areas of hematology, oncology, genetic disorders and autoimmune disease, and is actively seeking additional indications for its lead product.


News Articles [364 Associated News Articles listed on BioPortfolio]

rEVO Biologics announces submission of IND for ATryn in preeclampsia

rEVO Biologics, a subsidiary of LFB, has announced the submission of an investigational new drug (IND) application with the US Food and Drug Administration (FDA) for ATryn [antithrombin (recombinant)]...

rEVO Biologics begins Phase III trial of preeclampsia drug ATryn

US-based commercial-stage biopharmaceutical firm rEVO Biologics has started PRESERVE-1 Phase III clinical trial of ATryn [antithrombin (Recombinant)] to treat preeclampsia in pregnant women during the...

REVO seeks FDA nod to test blood clot drug for preeclampsia

Framingham, Mass.-based firm rEVO Biologics submitted an application to the FDA for approval to test its anticoagulant drug A -More- 

rEVO Biologics commences ATryn Phase 3 clinical program for treatment of preeclampsia in pregnant women

rEVO Biologics Inc., a subsidiary of LFB SA, today announced the initiation of the Phase 3 clinical program for ATryn for the treatment of preeclampsia in pregnant women during the 24th to 28th week o...

ShangPharma Biologics Head Mitchell Reff On Biologics R&D In China: An Interview With PharmAsia News

ShangPharma’s new Chief Biologic Officer Mitchell Reff discusses the company’s expansion into biologics and his views on biologics development in China.

Sequential Brands Group Pleased to Announce Victory at Daytona 24 Hours GTD Class With REVO Car

NEW YORK, Jan. 27, 2014 (GLOBE NEWSWIRE) -- Sequential Brands Group, Inc. (Nasdaq:SQBG) ("Sequential" or the "Company"), owner of the REVO brand, is pleased to announce the REVO co-sponsored Level 5...

Synthetic Biologics and Intrexon Corporation Initiate Development of Novel Biologics for a Subset of Patients Suffering from Irritable Bowel Syndrome (IBS)

ROCKVILLE, Md. and GERMANTOWN, Md., Dec. 9, 2013 /PRNewswire/ --Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of product candidates focused on the prevention and treatment of serious infe...

Synthetic Biologics: A Developer Of New Biologics Focused On Serious Infections

Following a failed drug, a company retrenches and reinvents itself as a developer of new biologics with novel mechanisms focused on serious infections and other diseases.

Drugs and Medications [3 Associated Drugs and Medications listed on BioPortfolio]

Standardized cat pelt [Jubilant HollisterStier LLC]

ALLERGENIC EXTRACT STANDARDIZED CAT PELT AP ACETONE PRECIPITATED

Standardized cat hair [Jubilant HollisterStier LLC]

ALLERGENIC EXTRACT STANDARDIZED CAT HAIR AP Acetone Precipitated

Cinryze [ViroPharma Biologics]

These highlights do not include all the information needed to use CINRYZE™ safely and effectively. See full prescribing information for CINRYZE.CINRYZE™ (C1 Esterase Inhibitor [Human]) For Intrave...

PubMed Articles [64 Associated PubMed Articles listed on BioPortfolio]

Factors associated with withdrawal of the anti-TNFα biologics in the treatment of rheumatic diseases: data from the Hong Kong Biologics Registry.

To study the factors associated with withdrawal of the and tumor necrosis factor alpha (anti-TNFα) biologics in the treatment of rheumatic diseases.

Biosimilar Granulocyte Colony-Stimulating Factor Uptakes in the EU-5 Markets: A Descriptive Analysis.

Biosimilars are copies of biological reference medicines. Unlike generics (copies of chemical molecules), biologics are complex, expensive and complicated to produce. The knowledge of the factors affe...

A170: Neoplasms in Pediatric Patients with Rheumatic Diseases Exposed to Biologics-A Quarternary Centre's Experience.

Biologic therapies have revolutionized the management of rheumatic diseases of childhood. However, these medications are associated with adverse effects including the possible development of neoplasms...

Advances in treating psoriasis.

Psoriasis is a T helper (Th)17/Th1-mediated autoimmune disease affecting the skin and joints. So far, distinct traditional oral compounds and modern biologics have been approved in most countries for...

Non-tumor necrosis factor-based biologic therapies for rheumatoid arthritis: present, future, and insights into pathogenesis.

The way rheumatoid arthritis is treated has changed dramatically with the introduction of anti-tumor necrosis factor (anti-TNF) biologics. Nevertheless, many patients still have less than adequate con...

Clinical Trials [21 Associated Clinical Trials listed on BioPortfolio]

Ustekinumab Safety and Surveillance Program Using the Ingenix NHI Database

The patients included in this observational study will be drawn from a research database containing claims and enrollment data for members of a large, geographically diverse US health plan...

Golimumab Safety and Surveillance Program Using the Ingenix NHI Database

The participants included in this observational study will be drawn from a research database containing claims and enrollment data for members of a large, geographically diverse US health...

Retrospective Evaluation of the Radiographic Efficacy of Conventional and Biologic Treatment

This study involves review and analysis of disease activity in patients with rheumatoid arthritis who where treated with either conventional DMARDs (Disease Modifying Antirheumatic Drugs)...

Positron Emission Tomography in Rheumatoid Arthritis With Adalimumab (PETRA)

Biologics are routinely used for the treatment of rheumatoid arthritis (RA). Adalimumab is a human monoclonal antibody that inhibit the Tumor Necrosis Factor alpha (TNF-alpha). Identificat...

Study of KB003 In Biologics-Inadequate Rheumatoid Arthritis

The purpose of this study is to evaluate the safety, pharmacokinetics, and efficacy of various repeat-dose regimens of KB003 in subjects with active Rheumatoid Arthritis (RA) who have had...

Companies [182 Associated Companies listed on BioPortfolio]

rEVO Biologics

rEVO Biologics is a rare disease company focused on developing and delivering first and next-generation therapeutics that are more cost effective to produce than traditional recom...

rEVO Biologics Inc.

rEVO Biologics Inc. (www.revobiologics.com) is a commercial-stage biopharmaceutical company focused on the development and commercialization of specialty therapeutics to address...

MSD Biologics (UK) Limited

Avecia Biologics was acquired in February 2010 by MSD, the UK subsidiary of Merck & Co Inc, the world’s second largest pharmaceutical company. MSD Billingham is one of the world's leading contract...

Precision Biologics, Inc.

Founded in February 2012 and commencing business in late September 2012, Precision Biologics, Inc. is a clinical stage biotechnology corporation focused on developing therapeutic...

GT Biologics

GT Biologics is focused on the research and development of Live Biotherapeutics (LBPs) for the treatment of autoimmune diseases. GT Biologics aim to deliver a new class of medicine based on the po...

More Information about "rEVO Biologics" on BioPortfolio

We have published hundreds of rEVO Biologics news stories on BioPortfolio along with dozens of rEVO Biologics Clinical Trials and PubMed Articles about rEVO Biologics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of rEVO Biologics Companies in our database. You can also find out about relevant rEVO Biologics Drugs and Medications on this site too.

Search BioPortfolio:
Advertisement

Corporate Database Quicklinks



Searches Linking to this Company Record

Advertisement